DE69521896T2 - Präparat auf lipidbasis, das diacylglyzerin, ein phospholipid, eine polare flüssigkeit und biologisch aktives material enthält - Google Patents

Präparat auf lipidbasis, das diacylglyzerin, ein phospholipid, eine polare flüssigkeit und biologisch aktives material enthält

Info

Publication number
DE69521896T2
DE69521896T2 DE69521896T DE69521896T DE69521896T2 DE 69521896 T2 DE69521896 T2 DE 69521896T2 DE 69521896 T DE69521896 T DE 69521896T DE 69521896 T DE69521896 T DE 69521896T DE 69521896 T2 DE69521896 T2 DE 69521896T2
Authority
DE
Germany
Prior art keywords
biologically active
active material
phase
phospholipid
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69521896T
Other languages
English (en)
Other versions
DE69521896D1 (de
Inventor
Helena Ljusberg-Wahren
Kare Larsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandberg Development AB
Original Assignee
GS Development AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GS Development AB filed Critical GS Development AB
Application granted granted Critical
Publication of DE69521896D1 publication Critical patent/DE69521896D1/de
Publication of DE69521896T2 publication Critical patent/DE69521896T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69521896T 1994-06-15 1995-05-24 Präparat auf lipidbasis, das diacylglyzerin, ein phospholipid, eine polare flüssigkeit und biologisch aktives material enthält Expired - Fee Related DE69521896T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9402106A SE518578C2 (sv) 1994-06-15 1994-06-15 Lipidbaserad komposition
PCT/SE1995/000593 WO1995034287A1 (en) 1994-06-15 1995-05-24 Lipid based composition containing diacylglycerol, phospholipid, polar liquid and biologically active material

Publications (2)

Publication Number Publication Date
DE69521896D1 DE69521896D1 (de) 2001-08-30
DE69521896T2 true DE69521896T2 (de) 2001-11-22

Family

ID=20394403

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69521896T Expired - Fee Related DE69521896T2 (de) 1994-06-15 1995-05-24 Präparat auf lipidbasis, das diacylglyzerin, ein phospholipid, eine polare flüssigkeit und biologisch aktives material enthält

Country Status (11)

Country Link
US (1) US5807573A (de)
EP (1) EP0767656B1 (de)
JP (1) JP3825468B2 (de)
AT (1) ATE203399T1 (de)
AU (1) AU2756395A (de)
CA (1) CA2192190C (de)
DE (1) DE69521896T2 (de)
FI (1) FI964959A0 (de)
NO (1) NO965380L (de)
SE (1) SE518578C2 (de)
WO (1) WO1995034287A1 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2726762B1 (fr) * 1994-11-10 1997-01-17 Oreal Composition cosmetique ou dermatologique sous forme d'une dispersion d'une phase huileuse dans une phase aqueuse stabilisee a l'aide de particules de gel cubique et son procede d'obtention
SE510363C2 (sv) * 1996-09-05 1999-05-17 Gs Dev Ab Användning av en flytande kristallin fas för att bestämma fördelningen av en kemisk substans mellan en hydrofob och en hydrofil miljö
SE511313C2 (sv) * 1997-01-13 1999-09-06 Gs Dev Ab Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol
CA2286052A1 (en) * 1997-04-17 1998-10-29 Lise Sylvest Nielsen A novel bioadhesive drug delivery system based on liquid crystals
AU735588B2 (en) 1997-09-18 2001-07-12 Pacira Pharmaceuticals, Inc. Sustained-release liposomal anesthetic compositions
ES2384094T3 (es) 1997-11-14 2012-06-29 Pacira Pharmaceuticals, Inc. Producción de liposomas multivesiculares
FR2780644B1 (fr) 1998-07-03 2001-07-20 Oreal Composition cosmetique ou dermatologique sous forme d'une dispersion d'une phase huileuse et d'une phase aqueuse, stabilisee a l'aide de particules de gel cubique
SE9802528D0 (sv) * 1998-07-13 1998-07-13 Gs Dev Ab Bone tissue restoring composition
SE514908C2 (sv) 1998-07-13 2001-05-14 Gs Dev Ab Medel för benrekonstruktion
GB9827034D0 (en) * 1998-12-10 1999-02-03 Univ Manchester Delivery formulation
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
US6800298B1 (en) 2000-05-11 2004-10-05 Clemson University Biological lubricant composition and method of applying lubricant composition
US20020153508A1 (en) * 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
DE10057769A1 (de) 2000-11-22 2002-05-23 Beiersdorf Ag Haarpflegeprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen
DE10057770A1 (de) * 2000-11-22 2002-05-23 Beiersdorf Ag Hautpflegeprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen ,
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
US6656385B2 (en) * 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6936187B2 (en) * 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
JP2004532252A (ja) * 2001-05-31 2004-10-21 スカイファーマ インコーポレーテッド リポソームおよびミクロスフェア中のナノ懸濁物のカプセル化
DE10127406A1 (de) * 2001-06-06 2002-12-12 Xzillion Gmbh & Co Kg Verfahren zur elektrophoretischen Trennung von Proben
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
WO2005046642A1 (en) * 2003-11-07 2005-05-26 Camurus Ab Compositions of lipids and cationic peptides
US8182834B2 (en) 2004-01-23 2012-05-22 Camurus Ab Ternary non-lamellar lipid compositions
EP1768650B1 (de) * 2004-06-04 2008-07-16 Camurus Ab Flüssige depotformulierungen
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
US20060127437A1 (en) * 2004-12-13 2006-06-15 Misty Anderson Kennedy Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids
US8535709B2 (en) * 2004-12-13 2013-09-17 Southeastern Medical Technologies, Llc Agents for controlling biological fluids and methods of use thereof
US20070059350A1 (en) * 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
ES2343641T3 (es) * 2005-01-14 2010-08-05 Camurus Ab Formulaciones bioadhesivas topicas.
EP1848403B8 (de) * 2005-01-14 2010-05-19 Camurus Ab Topische bioadhäsive formulierungen
PL1843746T3 (pl) * 2005-01-14 2011-09-30 Camurus Ab Formulacje analogów somatostatyny
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
DE602005026998D1 (de) * 2005-01-14 2011-04-28 Camurus Ab Somatostatin-analog-formulierungen
GB0501364D0 (en) * 2005-01-21 2005-03-02 Camurus Ab Compositions
EP1843751B1 (de) * 2005-01-21 2020-09-30 Camurus Ab Pharmazeutische lipid-zusammensetzungen
DK1888031T3 (da) 2005-06-06 2013-02-18 Camurus Ab GLP-1-analogformuleringer
US20070020228A1 (en) * 2005-07-22 2007-01-25 Williams Terry N Method of using a biosealant device
US20070092462A1 (en) * 2005-10-24 2007-04-26 Julio Gans Russ Cosmetic compositions
CN101309713A (zh) 2005-11-17 2008-11-19 周吉尼克斯股份有限公司 用无针注射递送粘稠制剂
BRPI0618861A2 (pt) * 2005-11-23 2011-09-13 Nestec Sa emulsão de óleo em água para a criação de novas consistências de produto e pó
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
US8568445B2 (en) 2007-08-21 2013-10-29 St. Jude Medical Puerto Rico Llc Extra-vascular sealing device and method
US8333787B2 (en) 2007-12-31 2012-12-18 St. Jude Medical Puerto Rico Llc Vascular closure device having a flowable sealing material
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
EP2052716B1 (de) * 2007-10-24 2014-12-31 Camurus AB Formulierungen mit gesteuerter Freisetzung
US8840640B2 (en) 2007-12-31 2014-09-23 St. Jude Medical Puerto Rico Llc Vascular closure device having an improved plug
EP2273880B1 (de) 2008-04-28 2014-12-31 Zogenix, Inc. Neuartige formulierungen zur behandlung von migräne
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
EP2165706A1 (de) 2008-09-18 2010-03-24 BioAlliance Pharma Behandlung von Entzündungsschmerzen der Mundhöhlenschleimhäute unter Verwendung von therapeutischen mukosalen, bioadhäsiven Trägern mit verlängerter Abgabe
WO2010057007A1 (en) * 2008-11-14 2010-05-20 Archer Daniels Midland Company Organogel compositions and processes for producing
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2011075623A1 (en) 2009-12-18 2011-06-23 Latitude Pharmaceuticals, Inc. One - phase gel compos ition compri s ing phos pholi pids
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
AU2012212066A1 (en) 2011-02-03 2013-08-15 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
CN103547258B (zh) 2011-03-17 2017-10-20 特兰斯德梅尔生物工艺股份有限公司 局部一氧化氮系统及其使用方法
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
BR112014013693B1 (pt) 2011-12-05 2023-01-31 Camurus Ab Pré-formulação, e, uso de uma pré-formulação
MX350964B (es) 2012-05-25 2017-09-27 Camurus Ab Formulaciones de agonistas del receptor de somatostatina.
EP2877155B1 (de) 2012-07-26 2020-10-28 Camurus AB Opioid-formulierungen
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586790B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
JP2020528900A (ja) 2017-07-27 2020-10-01 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 体脂肪低減のためのプロスタサイクリン受容体アゴニスト
WO2020059543A1 (ja) * 2018-09-20 2020-03-26 富士フイルム株式会社 生体材料
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
CN117794519A (zh) * 2021-07-27 2024-03-29 法纳克斯株式会社 非层状液晶形成性组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
SE8206744D0 (sv) * 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
SE457693B (sv) * 1986-07-01 1989-01-23 Drilletten Ab Komposition med reglerad frigoering vari ett biologiskt material aer loest eller dispergerat i en l2-fas
US5196201A (en) * 1989-10-20 1993-03-23 Bioapatite Ab Implant material composition, preparation thereof as well as uses thereof and implant product obtainable therefrom
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
US5262164A (en) * 1989-11-17 1993-11-16 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5164191A (en) * 1991-02-12 1992-11-17 Micro Vesicular Systems, Inc. Lipid vesicles having an alkyd as a wall-forming material
MX9202350A (es) * 1991-05-20 1992-11-01 Alza Corp Composiciones de incrementador de penetracion a la piel que usan monolinoleato de glicerol.

Also Published As

Publication number Publication date
NO965380D0 (no) 1996-12-13
SE518578C2 (sv) 2002-10-29
EP0767656A1 (de) 1997-04-16
CA2192190A1 (en) 1995-12-21
JPH10504532A (ja) 1998-05-06
CA2192190C (en) 2004-09-21
DE69521896D1 (de) 2001-08-30
FI964959A (fi) 1996-12-11
SE9402106D0 (sv) 1994-06-15
ATE203399T1 (de) 2001-08-15
FI964959A0 (fi) 1996-12-11
NO965380L (no) 1996-12-13
WO1995034287A1 (en) 1995-12-21
AU2756395A (en) 1996-01-05
JP3825468B2 (ja) 2006-09-27
EP0767656B1 (de) 2001-07-25
SE9402106L (sv) 1995-12-16
US5807573A (en) 1998-09-15

Similar Documents

Publication Publication Date Title
DE69521896D1 (de) Präparat auf lipidbasis, das diacylglyzerin, ein phospholipid, eine polare flüssigkeit und biologisch aktives material enthält
NO843023L (no) Fremgagsmaate for fremstilling av preparater med styrt frigivelse for biologisk aktive materialer og resulterende blandinger
ES542483A0 (es) Procedimiento de preparacion de una forma galenica para ad- ministracion por via oral
BR8007670A (pt) Dispersoes de copolimeros em compostos polifuncionais,tendo uma serie de hidrogenios ativos,metodo para fazer as dispersoes de copolimeros e uma composicao de poliuretana preparada
DE69715824T2 (de) Verfahren zur herstellung eines implantierbaren verbundwerkstoffs, so hergestellte werkstoffe, und kit zur durchführung des verfahrens
SE8602931D0 (sv) A controlled-release composition
DE2057957A1 (de) Neues Mittel zur Herstellung eines waessrigen Praeparates fuer kosmetische Zwecke
AU3590993A (en) Process and composition for microemulsion gel having bleaching and antiseptic properties
KR890700125A (ko) 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물
ES2055703T3 (es) Un procedimiento para preparar liposomas de doble capa sencillos.
TR199902025T2 (xx) Suda ileri derecede ��z�nmez olan bir etken maddeyi hapseden liyofilize lipozomlar i�eren farmas�tik preparasyon ve bu preparasyonu haz�rlamak i�in i�lem.
ES2042437T1 (es) Procedimiento de preparacion de una lipoproteina modificaa por incorporacion de una substancia activa lipofila.
FR2535969B1 (fr) Compose ether de polyol, son procede de preparation et composition cosmetique le contenant
DE69100161D1 (de) Herstellungsverfahren fuer ein haarkosmetikum, zusammensetzung und kosmetisches behandlungsverfahren.
EP0800822A3 (de) Verfahren zur Herstellung von geschlossenen Vesikeln durch Rehydratisierung von dehydratisierten Vesikeln
KR910021361A (ko) 항궤양 물질
IT8026979A0 (it) Attrattivo per insetti composito, per i maschi della nottuella delle messi, e procedimento per lapreparazione degli ingredienti attivi di esso.
SE8405118D0 (sv) 4-kloro-furo-(3,4-c)-pyridin-derivat forfarande for framstellning derav och terapeutiska kompositioner innehallande dem
NO155103C (no) Fremgangsmaate for fremstilling av substansen 41 200 rp etter isolering fra celler av stammen micrococcus sedogenes m 78.
ES530806A0 (es) 7, 8, 9, 10 tetrahidrotieno - 3,2-e - pirido - 4,3-b - indoles, procedimiento para su obtencion y los medicamentos que les contienen
ATA247680A (de) Verfahren zur herstellung von -9-hydrazono-6,7,8, 9-tetravaydro-4h-pyrido/1,2-a/ pyrimidin-4-on- derivaten sowie von deren physiologisch vertraeglichen salzen, hydraten und isomeren
ATA247380A (de) Verfahren zur herstellung von neuen, 3-substituierten 2-oxo-hexahydro-pyrimido (1,2-a)azepinen sowie von deren pharmazeutisch geeigneten salzen
CA2110491A1 (en) Gas filled liposomes and their use as ultrasonic contrast agents
TH13284EX (th) กรรมวิธีแบบต่อเนื่องสำหรับผลิตวัสดุที่คล้ายครีมหรือสารเปียกแบบนอน-นิวโทเนียน
AT325623B (de) Verfahren zur herstellung von neuen 1-substituierten 1,4-benzodiazepinen sowie deren säureadditionssalzen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee